Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP829459.RAjv6w_dVLR-j-bTzgN67b90ysjH7Oyzg45aVIWbNpyp0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP829459.RAjv6w_dVLR-j-bTzgN67b90ysjH7Oyzg45aVIWbNpyp0130_assertion type Assertion NP829459.RAjv6w_dVLR-j-bTzgN67b90ysjH7Oyzg45aVIWbNpyp0130_head.
- NP829459.RAjv6w_dVLR-j-bTzgN67b90ysjH7Oyzg45aVIWbNpyp0130_assertion description "[We determined the B2BKR genotype of 90 patients with essential hypertension and echocardiographically diagnosed LV hypertrophy, included in a double-blind study to receive treatment for 48 weeks with either the angiotensin II type 1 (AT1) receptor antagonist irbesartan or the beta1-adrenoceptor antagonist atenolol.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP829459.RAjv6w_dVLR-j-bTzgN67b90ysjH7Oyzg45aVIWbNpyp0130_provenance.
- NP829459.RAjv6w_dVLR-j-bTzgN67b90ysjH7Oyzg45aVIWbNpyp0130_assertion evidence source_evidence_literature NP829459.RAjv6w_dVLR-j-bTzgN67b90ysjH7Oyzg45aVIWbNpyp0130_provenance.
- NP829459.RAjv6w_dVLR-j-bTzgN67b90ysjH7Oyzg45aVIWbNpyp0130_assertion SIO_000772 12640257 NP829459.RAjv6w_dVLR-j-bTzgN67b90ysjH7Oyzg45aVIWbNpyp0130_provenance.
- NP829459.RAjv6w_dVLR-j-bTzgN67b90ysjH7Oyzg45aVIWbNpyp0130_assertion wasDerivedFrom befree-20140225 NP829459.RAjv6w_dVLR-j-bTzgN67b90ysjH7Oyzg45aVIWbNpyp0130_provenance.
- NP829459.RAjv6w_dVLR-j-bTzgN67b90ysjH7Oyzg45aVIWbNpyp0130_assertion wasGeneratedBy ECO_0000203 NP829459.RAjv6w_dVLR-j-bTzgN67b90ysjH7Oyzg45aVIWbNpyp0130_provenance.